论文部分内容阅读
目的研究子宫内膜异位症患者术后联合亮丙瑞林、达那唑治疗前后的血清CA125及骨密度的变化及疗效。方法经腹腔镜手术确诊后随机分为亮丙瑞林组和达那唑组药物治疗,所有患者于治疗前后3个月测定血清CA125、骨密度(BMD)值及疼痛VRS评分。结果亮丙瑞林治疗组患者CA125水平低于达那唑组,骨密度值、疼痛VRS评分明显高于达那唑组。结论①亮丙瑞林和达那唑均能有效治疗子宫内膜异位症,并控制其复发。②亮丙瑞林对患者骨密度的影响小于达那唑。
Objective To study the changes of serum CA125 and bone mineral density in patients with endometriosis combined with leuprolide and danazol before and after treatment. Methods After laparoscopic surgery, the patients were randomly divided into two groups: leuprolide group and danazol group. All patients were measured serum CA125, bone mineral density (BMD) and pain VRS score 3 months before and after treatment. Results The level of CA125 in the leuprorelin group was lower than that in the danazol group. The bone mineral density and pain VRS score were significantly higher than those in the danazol group. Conclusions ① Both leuprolide and danazol can effectively treat endometriosis and control its recurrence. ② Leuprorelin on bone mineral density in patients with less than danazol.